Geeta Singh Boora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Geeta Singh Boora has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anshika Chauhan
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 shared publications - Arnab Pal
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 shared publications - Sushmita Ghoshal
Department of Radiotherapy and Oncology, Tertiary Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 shared publications Himanshu Garg
2 shared publicationsJaimanti Bakshi
Department of ENT, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 shared publications- Jaimanti Bakshi
Department of Otorhinolaryngology and Head-Neck Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Scientific Reports
Exploring the biomarker potential of LCN2 and MMP9 proteins in Head and Neck Squamous Cell Carcinoma
- 26 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessExploring the biomarker potential of LCN2 and MMP9 proteins in Head and Neck Squamous Cell Carcinoma
- Open Access
- 10 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma
Metastatic dissemination is driven by rare Circulating Tumour Cells (CTCs) that exhibit pronounced phenotypic plasticity and dynamic interactions with different components in the bloodstream. In Oral Squamous Cell Carcinoma (OSCC), limited resolution of epithelial, mesenchymal, and platelet-associated CTC-states has constrained biological understanding of early tumour spread and hindered translational interpretation. In this study, we identify, count and characterize distinct epithelial, mesenchymal, and platelet-associated CTC-states in a cohort of 33 patients using a strategic workflow involving hematopoietic cell depletion with multiparametric flow-cytometric analysis. The FACS (Fluorescence-assisted cell sorting)-strategy incorporated epithelial tumour-associated markers (EpCAM, EGFR, and Cytokeratin), mesenchymal markers (VIM and N-Cadherin), and platelet/leukocyte markers (CD41 and CD45) to resolve biologically distinct CTC-subpopulations. Analytical robustness was established through spike-in experiments using OSCC cell line i.e., Cal27, demonstrating linear detection across clinically relevant ranges(1-100cells/mL of blood, Spearman’s r = 0.8738, p < 0.0001) and sensitive recovery of rare tumour cells with a Limit of Detection of 1 cell/mL, Limit of Quantification of 10 cells/mL, and Limit of Blank of 1.779 cells/mL. Molecular validation of sorted populations using whole transcriptome amplification-quantitative PCR confirmed tumour-associated marker expression and absence of hematopoietic contamination. Application of this approach in OSCC patients revealed detectable CTCs in 70% of the cases (ranging from 14.20 to 340.5 CTCs-related events/mL). Importantly, CTCs were identified across discrete phenotypic states, including platelet-associated CTC-clusters that were not captured by epithelial marker-restricted strategies. Quantitative comparison of CTC subtype proportions revealed majority (nearly 83%) of CTCs present as platelet clusters, followed by Epithelial-Single CTCs (21.21%). In comparison, CTCs with only mesenchymal phenotype constitute only 3.22% of the total CTC-population. Receiver operating characteristic analysis supported the discriminatory capacity of CTC enumeration and enabled the definition of a biologically relevant threshold of > 19.40 events mL for CTC positivity. Taken together, our findings outline a practical workflow for identifying and quantifying different CTC-states in OSCC, with platelet-associated CTCs emerging as the predominant population detected. These findings support the importance of incorporating phenotypic heterogeneity and platelet-associated tumour cell interactions into future liquid biopsy-based translational pathology research and clinical biomarker development in OSCC.
- 10 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIdentification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma
Metastatic dissemination is driven by rare Circulating Tumour Cells (CTCs) that exhibit pronounced phenotypic plasticity and dynamic interactions with different components in the bloodstream. In Oral Squamous Cell Carcinoma (OSCC), limited resolution of epithelial, mesenchymal, and platelet-associated CTC-states has constrained biological understanding of early tumour spread and hindered translational interpretation. In this study, we identify, count and characterize distinct epithelial, mesenchymal, and platelet-associated CTC-states in a cohort of 33 patients using a strategic workflow involving hematopoietic cell depletion with multiparametric flow-cytometric analysis. The FACS (Fluorescence-assisted cell sorting)-strategy incorporated epithelial tumour-associated markers (EpCAM, EGFR, and Cytokeratin), mesenchymal markers (VIM and N-Cadherin), and platelet/leukocyte markers (CD41 and CD45) to resolve biologically distinct CTC-subpopulations. Analytical robustness was established through spike-in experiments using OSCC cell line i.e., Cal27, demonstrating linear detection across clinically relevant ranges(1-100cells/mL of blood, Spearman’s r = 0.8738, p < 0.0001) and sensitive recovery of rare tumour cells with a Limit of Detection of 1 cell/mL, Limit of Quantification of 10 cells/mL, and Limit of Blank of 1.779 cells/mL. Molecular validation of sorted populations using whole transcriptome amplification-quantitative PCR confirmed tumour-associated marker expression and absence of hematopoietic contamination. Application of this approach in OSCC patients revealed detectable CTCs in 70% of the cases (ranging from 14.20 to 340.5 CTCs-related events/mL). Importantly, CTCs were identified across discrete phenotypic states, including platelet-associated CTC-clusters that were not captured by epithelial marker-restricted strategies. Quantitative comparison of CTC subtype proportions revealed majority (nearly 83%) of CTCs present as platelet clusters, followed by Epithelial-Single CTCs (21.21%). In comparison, CTCs with only mesenchymal phenotype constitute only 3.22% of the total CTC-population. Receiver operating characteristic analysis supported the discriminatory capacity of CTC enumeration and enabled the definition of a biologically relevant threshold of > 19.40 events mL for CTC positivity. Taken together, our findings outline a practical workflow for identifying and quantifying different CTC-states in OSCC, with platelet-associated CTCs emerging as the predominant population detected. These findings support the importance of incorporating phenotypic heterogeneity and platelet-associated tumour cell interactions into future liquid biopsy-based translational pathology research and clinical biomarker development in OSCC.
- Open Access
- 18 January 2025
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 7, 100289
PADI4 expression in baseline circulating tumour cells acts as a prognostic biomarker in oral squamous cell carcinoma
- 18 January 2025
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 7, 100289
Open AccessPADI4 expression in baseline circulating tumour cells acts as a prognostic biomarker in oral squamous cell carcinoma
- Open Access
- 8 February 2024
- Published by Elsevier in Oral Oncology Reports
- Vol. 9
Prosaposin – A plausible biomarker in head and neck squamous cell carcinoma
- 8 February 2024
- Published by Elsevier in Oral Oncology Reports
- Vol. 9
Open AccessProsaposin – A plausible biomarker in head and neck squamous cell carcinoma